Recce Pharmaceuticals Ltd. announced its primary anti-infective candidate, RECCE® 327 (R327), has been added to the World Health Organization?s (WHO) list of Antibacterial Agents in Clinical Development and Preclinical Development. The report covers traditional and non-traditional antibacterial agents in development worldwide and evaluates to what extent the present pipeline addresses infections caused by priority pathogens, according to the updated 2024 WHO bacterial priority pathogens list. The WHO has defined R327 as an ATP production disruptor and is the only compound under this category.

ATP is the source of energy for use and storage at the cellular level. Disruption of ATP production in bacterial cells, when targeted as the primary mechanism of action, not secondary to other cell perturbation mechanisms, carries the potential to confer activity against both Gram-positive and Gram-negative pathogens.